PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- And MEK/ERK-dependent pathways

Bioscience Reports

Volumn 34, Issue 2, 2014, Pages 59-67

  Fu, Xueqiong ^a   Feng, Jiarui ^b   Zeng, Duan ^a   Ding, Yu ^a   Yu, Changshou ^a   Yang, Bing ^a  

^a Affiliated to Guangzhou University of Traditional Chinese Medicine   (China)

^b Fifth Hospital of Wuhan   (China)

Author keywords

Cisplatin (CDDP); Gastric cancer; MEK ERK; p21 activated kinase 4 (PAK4); PI3K Akt

Indexed keywords

CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE; P21 ACTIVATED KINASE 4; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; MORPHOLINE DERIVATIVE; P21 ACTIVATED KINASE; PAK4 PROTEIN, HUMAN; PF 3758309; PYRAZOLE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENETICS; HUMAN; MAPK SIGNALING; METABOLISM; NUDE MOUSE; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CHROMONES; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MORPHOLINES; P21-ACTIVATED KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; PYRROLES; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897498352     PISSN: 01448463     EISSN: 15734935     Source Type: Journal    
DOI: 10.1042/BSR20130102     Document Type: Article

References (32)

1. Parkin, D. M. (2001) Global cancer statistics in the year 2000. Lancet Oncol. 2, 533-543
2. Beer, M., Cocconi, G., Ceci, G., Varini, M. and Cavalli, F. (1983) A phase II study of cisplatin in advanced gastric cancer. Eur. J. Cancer Clin. Oncol. 19, 717-720 (Pubitemid 13058366)
3. Altinbas, M., Er, O., Ozkan, M., Solak, Y., Coskun, H. S., Kucuk, C. and Gursy, S. (2005) Irinotecan plus cisplatin combination against metastatic gastric cancer: phase II study. Med. Oncol. 22, 153-160 (Pubitemid 41003448)
4. Park, K. W., Ahn, J. S., Park, Y. S., Lee, J., Kang, J. H., Park, J. O., Lim, H. Y., Im, Y. H., Kang, W. K., Park, K. and Lee, S. I. (2007) Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer. Cancer Chemother. Pharmacol. 59, 17-21 (Pubitemid 44796098)
5. Bokoch, G. M. (2003) Biology of the p21-activated kinases. Annu. Rev. Biochem. 72, 743-781
6. Ye, D. Z. and Field, J. (2012) PAK signaling in cancer. Cell Logist 2, 105-116
7. Li, X., Liu, F. and Li, F. (2010) PAK as a therapeutic target in gastric cancer. Expert Opin. Ther. Targets 14, 419-433
8. Nheu, T., He, H., Hirokawa, Y., Walker, F., Wood, J. and Maruta, H. (2004) PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition. Cell Cycle 3, 71-74 (Pubitemid 40268591)
9. Kiosses, W. B., Daniels, R. H., Otey, C., Bokoch, G. M. and Schwartz, M. A. (1999) A role for p21-activated kinase in endothelial cell migration. J. Cell Biol. 147, 831-844
10. Yang, Z., Rayala, S., Nguyen, D., Vadlamudi, R. K., Chen, S. and Kumar, R. (2005) Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions. Cancer Res. 65, 3179-3184 (Pubitemid 40524599)
11. Shalom-Barak, T. and Knaus, U. G. (2002) A p21-activated kinase-controlled metabolic switch up-regulates phagocyte NADPH oxidase. J. Biol. Chem. 277, 40659-40665 (Pubitemid 35215647)
12. Gururaj, A., Barnes, C. J., Vadlamudi, R. K. and Kumar, R. (2004) Regulation of phosphoglucomutase 1 phosphorylation and activity by a signaling kinase. Oncogene 23, 8118-8127 (Pubitemid 39531852)
13. Callow, M. G., Clairvoyant, F., Zhu, S., Schryver, B., Whyte, D. B., Bischoff, J. R., Jallal, B. and Smeal, T. (2002) Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J. Biol. Chem. 277, 550-558 (Pubitemid 34952091)
14. Paliouras, G. N., Naujokas, M. A. and Park, M. (2009) Pak4, a novel Gab1 binding partner, modulates cell migration and invasion by the Met receptor. Mol. Cell Biol. 29, 3018-3032
15. Ahn, H. K., Jang, J., Lee, J., Se Hoon, P., Park, J. O., Park, Y. S., Lim, H. Y., Kim, K. M. and Kang, W. K. (2011) P21-activated kinase 4 overexpression in metastatic gastric cancer patients. Transl. Oncol. 4, 345-349
16. Zhang, J., Wang, J., Guo, Q., Wang, Y., Zhou, Y., Peng, H., Cheng, M., Zhao, D. and Li, F. (2012) LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells. Cancer Lett. 317, 24-32
17. Murray, B. W., Guo, C., Piraino, J., Westwick, J. K., Zhang, C., Lamerdin, J., Dagostino, E., Knighton, D., Loi, C. M., Zager, M. et al. (2010) Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc. Natl. Acad. Sci. U.S.A. 107, 9446-9451
18. Wong, L. E., Chen, N., Karantza, V. and Minden, A. (2013) The Pak4 protein kinase is required for oncogenic transformation of MDA-MB-231 breast cancer cells. Oncogenesis 2, e50
19. Siu, M. K., Chan, H. Y., Kong, D. S., Wong, E. S., Wong, O. G., Ngan, H. Y., Tam, K. F., Zhang, H., Li, Z., Chan, Q. K. et al. (2010) p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proc. Natl. Acad. Sci. U.S.A. 107, 18622-18627
20. Ahmed, T., Shea, K., Masters, J. R., Jones, G. E. and Wells, C. M. (2008) A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Cell Signal. 20, 1320-1328
21. Park, M. H., Lee, H. S., Lee, C. S., You, S. T., Kim, D. J., Park, B. H., Kang, M. J., Heo, W. D., Shin, E. Y., Schwartz, M. A. and Kim, E. G. (2013) p21-Activated kinase 4 promotes prostate cancer progression through CREB. Oncogene 32, 2475-2482
22. Vivanco, I. and Sawyers, C. L. (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489-501 (Pubitemid 37328931)
23. Montagut, C. and Settleman, J. (2009) Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 283, 125-134
24. Sinnberg, T., Lasithiotakis, K., Niessner, H., Schittek, B., Flaherty, K. T., Kulms, D., Maczey, E., Campos, M., Gogel, J., Garbe, C. and Meier, F. (2009) Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J. Invest. Dermatol. 129, 1500-1515
25. Ohta, T., Ohmichi, M., Hayasaka, T., Mabuchi, S., Saitoh, M., Kawagoe, J., Takahashi, K., Igarashi, H., Du, B., Doshida, M. et al. (2006) Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology 147, 1761-1769
26. Cinti, C., Vindigni, C., Zamparelli, A., La Sala, D., Epistolato, M. C., Marrelli, D., Cevenini, G. and Tosi, P. (2008) Activated Akt as an indicator of prognosis in gastric cancer. Virchows Arch. 453, 449-455
27. West, K. A., Castillo, S. S. and Dennis, P. A. (2002) Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat. 5, 234-248 (Pubitemid 36132805)
28. Yeh, P. Y., Chuang, S. E., Yeh, K. H., Song, Y. C., Ea, C. K. and Cheng, A. L. (2002) Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochem. Pharmacol. 63, 1423-1430 (Pubitemid 34457957)
29. Lu, W., Xia, Y. H., Qu, J. J., He, Y. Y., Li, B. L., Lu, C., Luo, X. and Wan, X. P. (2013) p21-activated kinase 4 regulation of endometrial cancer cell migration and invasion involves the ERK1/2 pathway mediated MMP-2 secretion. Neoplasma 60, 493-503
30. Zhang, H. J., Siu, M. K., Yeung, M. C., Jiang, L. L., Mak, V. C., Ngan, H. Y., Wong, O. G., Zhang, H. Q. and Cheung, A. N. (2011) Overexpressed PAK4 promotes proliferation, migration and invasion of choriocarcinoma. Carcinogenesis 32, 765-771
31. Chan, P. M., Lim, L. and Manser, E. (2008) PAK is regulated by PI3K, PIX, CDC42, and PP2Calpha and mediates focal adhesion turnover in the hyperosmotic stress-induced p38 pathway. J. Biol. Chem. 283, 24949-24961
32. Tang, Y., Zhou, H., Chen, A., Pittman, R. N. and Field, J. (2000) The Akt proto-oncogene links Ras to Pak and cell survival signals. J. Biol. Chem. 275, 9106-9109 (Pubitemid 30185123)